Drug intelligence / Profile preview

CE119

Development stage: Preclinical
Lead developer: Cello Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

CE119 is a preclinical-stage small molecule chemotherapy agent being developed by Cello Therapeutics. It is formulated using the company's proprietary Cellular Nanoparticle (CNP) platform technology, which involves coating drug payloads with natural cellular membranes to create biomimetic nanoparticles. This delivery system is designed to improve the targeted delivery of chemotherapy agents to tumor sites, potentially enhancing efficacy while reducing systemic toxicity. CE119 is currently under investigation for the treatment of colorectal cancer.

Beyond the preview

Go deeper on CE119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE119.

Explore the full profile